Martha Brown
Executive Director, Research Coordination, Boehringer Ingelheim
Martha Brown
Executive Director, Research Coordination, Boehringer Ingelheim
Martha Brown is currently Executive Director, Research Coordination at Boehringer Ingelheim in Ridgefield, CT. She received her BS in Biochemistry from Manhattan College and earned a PhD in Biology from John Hopkins University. Martha conducted her postdoc at the University of Wisconsin-Madison, studying protein-DNA interactions. She then joined Boehringer Ingelheim, initially working on a development program that then become a treatment for HIV infection. Martha then moved to Discovery Research, most recently leading high-throughput screening, structural biology and SAR testing for all US small molecule programs. She assumed her current role leading the US Research Coordination department seven years ago.
Ralph Torbay
SVP, Commercial, Immunocore
Ralph Torbay
SVP, Commercial, Immunocore
Product: KIMMTRAK®
Company: Immunocore
About the Product:
KIMMTRAK® (tebentafusp-tebn) became the world’s first T cell receptor (TCR) therapy, and the first and only FDA-approved treatment for HLA-A*02:01-positive metastatic or unresectable uveal melanoma – a disease which, until 2022, had an anticipated median overall survival of approximately 12 months. KIMMTRAK is a soluble bispecific protein comprised of an engineered TCR targeting gp100, an antigen expressed in melanocytes and melanoma, to an anti-CD3 immune-effector function, which attracts and activates T cells to kill tumor cells. KIMMTRAK is the first therapy developed using Immunocore’s pioneering ImmTAX® (Immune Mobilizing Monoclonal TCRs Against X disease) platform, a first-in-class immunotherapy platform with a novel mechanism of action.